IC
MLAB icon

Innealta Capital’s Mesa Laboratories MLAB Stock Holding History

Innealta Capital’s Portfolio MLAB Stock Details MLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$174 – 1076
2024
Q2 		$174 Buy
+2
New +$209 ﹤0.01% 1629

Other funds holding MLAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Innealta Capital's MLAB Position: Q3 2024 in Review

Innealta Capital sold out of Mesa Laboratories (MLAB) in Q3 2024, closing a stake of 2 shares — an estimated $174 sold.

Innealta Capital first reported a position in MLAB in Q2 2024 and held it in 1 quarter. The position peaked at $174 in Q2 2024. 166 funds tracked by Wall St. Rank hold MLAB as of Q3 2024.

  • Innealta Capital reported no remaining Mesa Laboratories position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 2 Mesa Laboratories shares in Q3 2024, an estimated $174.
  • Innealta Capital first reported a position in Mesa Laboratories in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Mesa Laboratories position peaked at $174 in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Mesa Laboratories as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.